SEC 13F Intelligence

Managers / Q2 2020 · view latest →

Rock Springs Capital Management LP

CIK 0001595725 · 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE, MD, 21202 · 4102200129

Reported Value
$3.6B
Q2 2020
Positions
143
Filings on Record
30
2019–present window
Filed
Aug 14, 2020
original filing

Summary

Rock Springs Capital Management LP reported $3.6B in U.S.-listed holdings across 143 positions for Q2 2020.

Its largest position, NBIX, represents 4.6% of the portfolio.

Compared with Q1 2020, the fund opened 16 new positions and exited 4.

Portfolio Metrics

Turnover
+2.5%
vs prior filed quarter
Top-10 Concentration
+23.5%
share of reported value
Largest Position
+4.6%
Neurocrine Biosciences
New / Exited
16 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.1BQ4 ’18Q1 ’19: $2.6BQ2 ’19: $2.8BQ3 ’19: $2.5BQ4 ’19: $3.2BQ4 ’19Q1 ’20: $2.4BQ2 ’20: $3.6BQ3 ’20: $3.9BQ4 ’20: $4.7BQ4 ’20Q1 ’21: $4.6BQ2 ’21: $5.1BQ3 ’21: $4.8BQ4 ’21: $4.3BQ4 ’21Q1 ’22: $4.0BQ2 ’22: $3.4BQ3 ’22: $3.9BQ4 ’22: $4.2BQ4 ’22Q1 ’23: $4.2BQ2 ’23: $4.2BQ3 ’23: $3.7BQ4 ’23: $4.1BQ4 ’23Q1 ’24: $3.9BQ2 ’24: $3.3BQ3 ’24: $3.1BQ4 ’24: $2.6BQ4 ’24Q1 ’25: $1.7BQ2 ’25: $1.6BQ3 ’25: $1.7BQ4 ’25: $2.0BQ4 ’25Q1 ’26: $1.7Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 80.3%Other: 11.3%ADR: 7.0%US DOMESTIC: 1.4%Right: 0.0%
  • Common Stock · 80.3% · $2.9B
  • Other · 11.3% · $413M
  • ADR · 7.0% · $255M
  • US DOMESTIC · 1.4% · $49M
  • Right · 0.0% · $663,000

Quarter-over-Quarter Changes full breakdown →

vs Q1 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NVV1NOVAVAX INCNEW+570.6K570.6K+$48M$48M
ROYALTY PHARMA PLCNEW+500.0K500.0K+$24M$24M
ALXNALEXION PHARMACEUTICALS INCNEW+183.5K183.5K+$21M$21M
FUSION PHARMACEUTICALS INCNEW+937.0K937.0K+$16M$16M
GOSSAMER BIO INCNEW+15.57M15.57M+$16M$16M
TGTXTG THERAPEUTICS INCNEW+682.9K682.9K+$13M$13M
BFAMBRIGHT HORIZONS FAM SOL IN DNEW+98.5K98.5K+$12M$12M
SWAVUSDSHOCKWAVE MED INCNEW+197.5K197.5K+$9M$9M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2020

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1NBIXNEUROCRINE BIOSCIENCES INChistory →COM4.57%$167M1.37M
2UNHUNITEDHEALTH GROUP INChistory →COM3.28%$119M405.0K
3CNCCENTENE CORP DELhistory →COM2.29%$84M1.31M
4IRTCIRHYTHM TECHNOLOGIES INChistory →COM2.07%$75M651.0K
52655787DBLUEPRINT MEDICINES CORPhistory →COM2.05%$75M960.0K
6HUMHUMANA INChistory →COM2.03%$74M191.0K
7ISRGINTUITIVE SURGICAL INChistory →COM NEW1.88%$68M120.0K
8ZLABZAI LAB LTDhistory →ADR1.83%$67M813.2K
9ARGXARGENX SEhistory →SPONSORED ADR1.78%$65M287.5K
10AGIOAGIOS PHARMACEUTICALS INChistory →COM1.73%$63M1.18M
11IMMUIMMUNOMEDICS INChistory →COM1.63%$59M1.68M
12PODDINSULET CORPhistory →COM1.56%$57M293.0K
13BAXBAXTER INTL INChistory →COM1.52%$56M645.0K
14SRPTSAREPTA THERAPEUTICS INChistory →COM1.52%$55M345.5K
15HCAHCA HEALTHCARE INChistory →COM1.46%$53M549.5K
16EHCENCOMPASS HEALTH CORPhistory →COM1.41%$52M832.5K
17ACADACADIA PHARMACEUTICALS INChistory →COM1.40%$51M1.05M
18ALNYALNYLAM PHARMACEUTICALS INChistory →COM1.40%$51M345.0K
19RAREULTRAGENYX PHARMACEUTICAL INhistory →COM1.39%$51M646.8K
20PCRXPACIRA BIOSCIENCEShistory →COM1.33%$49M925.0K
21BIIBBIOGEN INChistory →COM1.32%$48M180.0K
22BMRNBIOMARIN PHARMACEUTICAL INChistory →COM1.31%$48M387.5K
23NVV1NOVAVAX INChistory →COM NEW1.30%$48M570.6K
24TFXTELEFLEX INCORPORATEDhistory →COM1.30%$47M130.0K
25NVROEURNEVRO CORPhistory →COM1.26%$46M386.0K
26INVITAE CORPCOM1.26%$46M1.51M
27MERSANA THERAPEUTICS INCCOM1.21%$44M1.88M
28SGENUSDSEATTLE GENETICS INChistory →COM1.17%$42M250.0K
29PTLAEURPORTOLA PHARMACEUTICALS INChistory →COM1.14%$41M2.31M
30IDXXIDEXX LABS INChistory →COM1.13%$41M125.0K
31ONCBEIGENE LTDhistory →SPONSORED ADR1.11%$41M215.0K
32EWEDWARDS LIFESCIENCES CORPhistory →COM1.10%$40M582.0K
33FRPTFRESHPET INChistory →COM1.09%$40M476.0K
34MRTXEURMIRATI THERAPEUTICS INChistory →COM1.09%$40M348.8K
35AFWALIGN TECHNOLOGY INChistory →COM1.08%$39M143.0K
36BSXBOSTON SCIENTIFIC CORPhistory →COM1.06%$39M1.10M
37PENPENUMBRA INChistory →COM1.02%$37M207.0K
38EXKEXACT SCIENCES CORPhistory →COM1.01%$37M424.0K
39VRTXVERTEX PHARMACEUTICALS INChistory →COM1.00%$36M125.0K
40CHRSCOHERUS BIOSCIENCES INChistory →COM0.99%$36M2.03M
41APLTAPPLIED THERAPEUTICS INChistory →COM0.98%$36M991.6K
42ASSEMBLY BIOSCIENCES INCCOM0.96%$35M1.50M
43ARDXARDELYX INChistory →COM0.95%$35M5.02M
44GALAPAGOS NVSPON ADR0.95%$35M175.0K
45EPZMEUREPIZYME INChistory →COM0.93%$34M2.10M
46AMARIN CORP PLCSPONS ADR NEW0.88%$32M4.65M
47ASCENDIS PHARMA A SSPONSORED ADR0.87%$32M213.5K
48CICIGNA CORP NEWhistory →COM0.83%$30M161.0K
49AMGNAMGEN INChistory →COM0.82%$30M126.0K
50MDGLMADRIGAL PHARMACEUTICALS INChistory →COM0.79%$29M254.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.7B100May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.0B99Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.7B93Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.6B93Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.7B96May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$2.6B107Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$3.1B109Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$3.3B112Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$3.9B114May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$4.1B104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$3.7B120Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$4.2B123Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$4.2B121May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$4.2B120Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$3.9B128Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$3.4B131Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$4.0B135May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$4.3B136Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$4.8B153Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$5.1B156Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$4.6B151May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$4.7B155Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$3.9B148Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$3.6B143Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.4B131May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$3.2B130Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$2.5B138Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.8B135Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.6B131May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.1B133Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.